sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe
Company profile
Ticker
PCVX
Exchange
Website
CEO
Grant Pickering
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SutroVax, Inc.
SEC CIK
Corporate docs
Subsidiaries
Vaxcyte Switzerland GmbH ...
IRS number
464233385
PCVX stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
8 May 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
424B5
Prospectus supplement for primary offering
31 Jan 24
8-K
Other Events
31 Jan 24
Latest ownership filings
4
Mikhail Eydelman
3 May 24
4
Jim Wassil
3 May 24
4
GRANT PICKERING
3 May 24
144
Notice of proposed sale of securities
1 May 24
144
Notice of proposed sale of securities
1 May 24
144
Notice of proposed sale of securities
1 May 24
4
GRANT PICKERING
25 Apr 24
144
Notice of proposed sale of securities
23 Apr 24
4
ANDREW GUGGENHIME
22 Apr 24
4
Jim Wassil
19 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm | 546.24 mm |
Cash burn (monthly) | (no burn) | (no burn) | 37.68 mm | 29.83 mm | 19.18 mm | 19.43 mm |
Cash used (since last report) | n/a | n/a | 277.61 mm | 219.79 mm | 141.35 mm | 143.19 mm |
Cash remaining | n/a | n/a | 268.63 mm | 326.45 mm | 404.89 mm | 403.04 mm |
Runway (months of cash) | n/a | n/a | 7.1 | 10.9 | 21.1 | 20.7 |
Institutional ownership, Q4 2023
6.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 3 |
Closed positions | 184 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 22.30 bn |
Total shares | 7.46 mm |
Total puts | 5.00 k |
Total calls | 5.00 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Longitude Capital Partners II | 3.11 mm | $82.54 mm |
Roche Finance | 2.33 mm | $55.53 mm |
Longitude Venture Partners II | 1.61 mm | $38.22 mm |
Moody Aldrich Partners | 147.93 k | $9.29 bn |
Raymond James & Associates | 51.55 k | $3.24 bn |
Mirae Asset Global Investments | 51.14 k | $3.21 bn |
Mutual Of America Capital Management | 48.33 k | $3.04 bn |
China Universal Asset Management | 42.17 k | $2.65 mm |
Allspring Global Investments | 22.60 k | $1.42 bn |
Arizona State Retirement System | 20.99 k | $1.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 63.84 | 46 | 2.94 k | 146,054 |
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 62.066 | 582 | 36.12 k | 146,100 |
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 61.282 | 680 | 41.67 k | 146,682 |
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 63.87 | 72 | 4.60 k | 146,054 |
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 62.006 | 508 | 31.50 k | 146,126 |
1 May 24 | Grant Pickering | Common Stock | Sell | Dispose S | Yes | Yes | 61.251 | 728 | 44.59 k | 146,634 |
1 May 24 | Mikhail Eydelman | Common Stock | Sell | Dispose S | No | Yes | 63.903 | 144 | 9.20 k | 30,597 |
1 May 24 | Mikhail Eydelman | Common Stock | Sell | Dispose S | No | Yes | 61.948 | 559 | 34.63 k | 30,741 |
1 May 24 | Mikhail Eydelman | Common Stock | Sell | Dispose S | No | Yes | 61.297 | 964 | 59.09 k | 31,300 |
1 May 24 | Mikhail Eydelman | Common Stock | Option exercise | Acquire M | No | No | 21.41 | 1,667 | 35.69 k | 32,264 |
News
Cantor Fitzgerald Reiterates Overweight on Vaxcyte
9 May 24
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
9 May 24
Vaxcyte Q1 EPS $(0.85) Beats $(1.09) Estimate
8 May 24
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
10 Apr 24
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
10 Apr 24